CSIMarket


Nuo Therapeutics Inc   (NUOT)
Other Ticker:  
 


 

Nuo Therapeutics Inc

NUOT's Financial Statements and Analysis



Nuo Therapeutics Inc increased third quarter of 2023 net loss per share of $-0.02 compare to net loss per share of $-0.02 recorded in the same quarter a year ago a decrease compare to $-0.02 realized in previous quarter.


third quarter of 2023
Earnings Per Share Revenues
$ -0.02 $  0 Mill
Unch.     Unch.     +507.17 %



Nuo Therapeutics Inc 's Revenue rose by 507.17 % in third quarter of 2023 (Sep 30 2023) year on year, to $0 million and advanced by 96.53 % sequentially.


Nuo Therapeutics Inc is Expected to report next financial results on April 13, 2024.

More on NUOT's Income Statement



Nuo Therapeutics Inc 's in thethird quarter of 2023 recorded net loss of $-0.791 million, an improvement compare to net loss of $-0.913 million in III. Quarter a year ago.

Sequentially net loss narrowed from net loss of $-0.872 million realized in previous quarter.

More on NUOT's Growth

Nuo Therapeutics Inc Inventories
Inventories declined by -20.84 % to $0.21 million from III. Quarter a year ago, sequentially inventories fell by -7.15 %. NUOT's Cash flow In the third quarter of 2023 company's net cash flow was $0 million

More on NUOT's Cash flow Statement


Nuo Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Nuo Therapeutics Inc earned $ 0.03 cash per share, on a free-cash flow basis .

Book value grew by 53.09 % sequentially to $0.02 per share.
Tangible Book value grew to $ 0.02 per share from $ 0.01.

Company issued 0.34 million shares or 0.82 % in Sep 30 2023.


More on NUOT's Dividends

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) 42
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Nuo Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Nuo Therapeutics Inc had $ 0.03 cash flow per share, on a free-cash flow basis .

Book value grew by 53.09 % sequentially to $0.02 per share.
Tangible Book value grew to $ 0.02 per share from $ 0.01.

Company issued 0.34 million shares or 0.82 % in Sep 30 2023.


More on NUOT's Balance Sheets

 Market Capitalization (Millions) -
 Shares Outstanding (Millions) 42
 Total Debt (Millions $) -
 Revenue (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -3
 Cash Flow (TTM) (Millions $) -1
 Capital Exp. (TTM) (Millions $) 0
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Nuo Therapeutics Inc Earnings

Strong Third-Quarter Performance Positions Nuo Therapeutics Inc. as a Dominant Player in Medical Equipment & Supplies Industry

Nuo Therapeutics Inc: A Bullish Outlook for Future Growth
Nuo Therapeutics Inc, a leading Medical Equipment and Supplies company, recently reported third-quarter earnings that exceeded industry expectations. With a remarkable revenue rise of 507.166% year on year to $0.23 million, Nuo Therapeutics has demonstrated its robustness and resilience in the market. Although the company experienced a loss at $-0.02 per share, its strong revenue growth far outweighs this setback.
When compared to its industry peers, Nuo Therapeutics has clearly outperformed. The Medical Equipment and Supplies industry, as a whole, has averaged a revenue increase of just 4.80% during the same period. This significant gap in re...

Nuo Therapeutics Sets the Stage for Explosive Growth with Revenue Surpassing $0.1 Million in Latest Fiscal Period



The stock market is known for its unpredictable nature, providing investors with opportunities for significant gains or losses. One company that recently made headlines is Nuo Therapeutics Inc. In this article, we will delve into the financial performance of this medical equipment and supplies company, uncovering interesting facts and shedding light on its outlook.
Revenue and Net Loss:
Nuo Therapeutics Inc reported a revenue of $0.118169 million during the fiscal period ending June 30, 2023. This signifies a positive growth trajectory for the company, as it showcases an improvement compared to the same reporting period a year ago, which saw a net loss of $-0.924 million. However, the recen...

Nuo Therapeutics Inc Outperforms Market Challenges with Improved Inventory Turnover Ratio in Q1 2023

Nuo Therapeutics Inc Inventory Turnover Ratio Improves in Q1 2023
Nuo Therapeutics Inc, a healt...


Date modified: 2023-11-21T19:38:44+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com